Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention

Sudden cardiac death (SCD) is one of the leading causes of mortality in developed countries. Internal cardioverter defibrillators (ICDs) have been developed to treat potentially life-threatening ventricular arrhythmias. Multiple randomised trials have been completed to assess the efficacy of primary...

Full description

Saved in:
Bibliographic Details
Published in:Arrhythmia & electrophysiology review 2012-09, Vol.1 (1), p.46-50
Main Authors: Silverstein, Joshua R, Katritsis, Demosthenes G, Josephson, Mark E
Format: Article
Language:English
Subjects:
Asymptomatic
Beta blockers
Cardiac arrhythmia
Cardiomyopathy
Cardiovascular disease
Coronary vessels
Defibrillators
Device Therapy
Heart attacks
Heart failure
Ischemia
Mortality
Prevention
Transplants & implants
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c348t-d8b013a9b14511864b5dacae1de28242a4ec59696bad60059351bc58ca966d833
cites
container_end_page 50
container_issue 1
container_start_page 46
container_title Arrhythmia & electrophysiology review
container_volume 1
creator Silverstein, Joshua R
Katritsis, Demosthenes G
Josephson, Mark E
description Sudden cardiac death (SCD) is one of the leading causes of mortality in developed countries. Internal cardioverter defibrillators (ICDs) have been developed to treat potentially life-threatening ventricular arrhythmias. Multiple randomised trials have been completed to assess the efficacy of primary prevention ICDs in selected populations. In response to the randomised, controlled trials guidelines have been established to help guide physicians in choosing appropriate patients who may benefit from primary prevention ICDs. Unfortunately, many patients who currently fall within the guidelines are either not represented in the clinical trials or disregarded. The morbidity associated with ICD implant is also overlooked and the cost-benefit analyses are exaggerated in favour of ICD implant. This review article summarises major clinical trials addressing primary prevention ICDs, and also highlights the evidence supporting the use and abuse of ICDs.
doi_str_mv 10.15420/aer.2012.1.46
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4711493</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1762345229</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-d8b013a9b14511864b5dacae1de28242a4ec59696bad60059351bc58ca966d833</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMottRuXcqAGzcd855kI5T6hIIu7DokMxlNmU5qMlPw35vaWtTVvSFfTs69B4BzBHPEKIbX2oYcQ4RzlFN-BIYYMjghpCiODz2XAzCOcQkhRJwhJPEpGGAuCINYDsF8EW2m2yqbmj51vs6e2s6GVjfZTIfK-Y0N6Zzd2tqZ4JpGdz7ErPYhewlupcNnqnZj28759gyc1LqJdryvI7C4v3udPU7mzw9Ps-l8UhIqukklDERES4NoMiQ4NazSpbaoslhgijW1JZNccqMrDiGThCFTMlFqyXklCBmBm53uujcrW5Xp96Abtd4ZUl479femde_qzW8ULRCicitwtRcI_qO3sVMrF0ubpmut76NCBceEMoxlQi__oUvfb_cTVdqiwJiRAicq31Fl8DEGWx_MIKi-s1IpK7XNSiFFeXpw8XuEA_6TDPkC0wGPfw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2688225372</pqid></control><display><type>article</type><title>Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Silverstein, Joshua R ; Katritsis, Demosthenes G ; Josephson, Mark E</creator><creatorcontrib>Silverstein, Joshua R ; Katritsis, Demosthenes G ; Josephson, Mark E ; Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US ; Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Baker 4, Boston, MA 02215, US. E: mjoseph2@bidmc.harvard.edu ; Athens Euroclinic, Athens, Greece; St Thomas’s Hospital, London, UK</creatorcontrib><description>Sudden cardiac death (SCD) is one of the leading causes of mortality in developed countries. Internal cardioverter defibrillators (ICDs) have been developed to treat potentially life-threatening ventricular arrhythmias. Multiple randomised trials have been completed to assess the efficacy of primary prevention ICDs in selected populations. In response to the randomised, controlled trials guidelines have been established to help guide physicians in choosing appropriate patients who may benefit from primary prevention ICDs. Unfortunately, many patients who currently fall within the guidelines are either not represented in the clinical trials or disregarded. The morbidity associated with ICD implant is also overlooked and the cost-benefit analyses are exaggerated in favour of ICD implant. This review article summarises major clinical trials addressing primary prevention ICDs, and also highlights the evidence supporting the use and abuse of ICDs.</description><identifier>ISSN: 2050-3369</identifier><identifier>ISSN: 2050-3377</identifier><identifier>EISSN: 2050-3377</identifier><identifier>DOI: 10.15420/aer.2012.1.46</identifier><identifier>PMID: 26835029</identifier><language>eng</language><publisher>England: Radcliffe Medical Education Ltd</publisher><subject>Asymptomatic ; Beta blockers ; Cardiac arrhythmia ; Cardiomyopathy ; Cardiovascular disease ; Coronary vessels ; Defibrillators ; Device Therapy ; Heart attacks ; Heart failure ; Ischemia ; Mortality ; Prevention ; Transplants &amp; implants</subject><ispartof>Arrhythmia &amp; electrophysiology review, 2012-09, Vol.1 (1), p.46-50</ispartof><rights>2012. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.aerjournal.com/guideline/about-aer#listItem1.8.</rights><rights>Copyright © 2012, Radcliffe Cardiology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-d8b013a9b14511864b5dacae1de28242a4ec59696bad60059351bc58ca966d833</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2688225372/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2688225372?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,75126</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26835029$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Silverstein, Joshua R</creatorcontrib><creatorcontrib>Katritsis, Demosthenes G</creatorcontrib><creatorcontrib>Josephson, Mark E</creatorcontrib><creatorcontrib>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US</creatorcontrib><creatorcontrib>Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Baker 4, Boston, MA 02215, US. E: mjoseph2@bidmc.harvard.edu</creatorcontrib><creatorcontrib>Athens Euroclinic, Athens, Greece; St Thomas’s Hospital, London, UK</creatorcontrib><title>Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention</title><title>Arrhythmia &amp; electrophysiology review</title><addtitle>Arrhythm Electrophysiol Rev</addtitle><description>Sudden cardiac death (SCD) is one of the leading causes of mortality in developed countries. Internal cardioverter defibrillators (ICDs) have been developed to treat potentially life-threatening ventricular arrhythmias. Multiple randomised trials have been completed to assess the efficacy of primary prevention ICDs in selected populations. In response to the randomised, controlled trials guidelines have been established to help guide physicians in choosing appropriate patients who may benefit from primary prevention ICDs. Unfortunately, many patients who currently fall within the guidelines are either not represented in the clinical trials or disregarded. The morbidity associated with ICD implant is also overlooked and the cost-benefit analyses are exaggerated in favour of ICD implant. This review article summarises major clinical trials addressing primary prevention ICDs, and also highlights the evidence supporting the use and abuse of ICDs.</description><subject>Asymptomatic</subject><subject>Beta blockers</subject><subject>Cardiac arrhythmia</subject><subject>Cardiomyopathy</subject><subject>Cardiovascular disease</subject><subject>Coronary vessels</subject><subject>Defibrillators</subject><subject>Device Therapy</subject><subject>Heart attacks</subject><subject>Heart failure</subject><subject>Ischemia</subject><subject>Mortality</subject><subject>Prevention</subject><subject>Transplants &amp; implants</subject><issn>2050-3369</issn><issn>2050-3377</issn><issn>2050-3377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpdkUtLAzEUhYMottRuXcqAGzcd855kI5T6hIIu7DokMxlNmU5qMlPw35vaWtTVvSFfTs69B4BzBHPEKIbX2oYcQ4RzlFN-BIYYMjghpCiODz2XAzCOcQkhRJwhJPEpGGAuCINYDsF8EW2m2yqbmj51vs6e2s6GVjfZTIfK-Y0N6Zzd2tqZ4JpGdz7ErPYhewlupcNnqnZj28759gyc1LqJdryvI7C4v3udPU7mzw9Ps-l8UhIqukklDERES4NoMiQ4NazSpbaoslhgijW1JZNccqMrDiGThCFTMlFqyXklCBmBm53uujcrW5Xp96Abtd4ZUl479femde_qzW8ULRCicitwtRcI_qO3sVMrF0ubpmut76NCBceEMoxlQi__oUvfb_cTVdqiwJiRAicq31Fl8DEGWx_MIKi-s1IpK7XNSiFFeXpw8XuEA_6TDPkC0wGPfw</recordid><startdate>20120901</startdate><enddate>20120901</enddate><creator>Silverstein, Joshua R</creator><creator>Katritsis, Demosthenes G</creator><creator>Josephson, Mark E</creator><general>Radcliffe Medical Education Ltd</general><general>Radcliffe Cardiology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120901</creationdate><title>Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention</title><author>Silverstein, Joshua R ; Katritsis, Demosthenes G ; Josephson, Mark E</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-d8b013a9b14511864b5dacae1de28242a4ec59696bad60059351bc58ca966d833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Asymptomatic</topic><topic>Beta blockers</topic><topic>Cardiac arrhythmia</topic><topic>Cardiomyopathy</topic><topic>Cardiovascular disease</topic><topic>Coronary vessels</topic><topic>Defibrillators</topic><topic>Device Therapy</topic><topic>Heart attacks</topic><topic>Heart failure</topic><topic>Ischemia</topic><topic>Mortality</topic><topic>Prevention</topic><topic>Transplants &amp; implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silverstein, Joshua R</creatorcontrib><creatorcontrib>Katritsis, Demosthenes G</creatorcontrib><creatorcontrib>Josephson, Mark E</creatorcontrib><creatorcontrib>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US</creatorcontrib><creatorcontrib>Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Baker 4, Boston, MA 02215, US. E: mjoseph2@bidmc.harvard.edu</creatorcontrib><creatorcontrib>Athens Euroclinic, Athens, Greece; St Thomas’s Hospital, London, UK</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Arrhythmia &amp; electrophysiology review</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silverstein, Joshua R</au><au>Katritsis, Demosthenes G</au><au>Josephson, Mark E</au><aucorp>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, US</aucorp><aucorp>Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Road, Baker 4, Boston, MA 02215, US. E: mjoseph2@bidmc.harvard.edu</aucorp><aucorp>Athens Euroclinic, Athens, Greece; St Thomas’s Hospital, London, UK</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention</atitle><jtitle>Arrhythmia &amp; electrophysiology review</jtitle><addtitle>Arrhythm Electrophysiol Rev</addtitle><date>2012-09-01</date><risdate>2012</risdate><volume>1</volume><issue>1</issue><spage>46</spage><epage>50</epage><pages>46-50</pages><issn>2050-3369</issn><issn>2050-3377</issn><eissn>2050-3377</eissn><abstract>Sudden cardiac death (SCD) is one of the leading causes of mortality in developed countries. Internal cardioverter defibrillators (ICDs) have been developed to treat potentially life-threatening ventricular arrhythmias. Multiple randomised trials have been completed to assess the efficacy of primary prevention ICDs in selected populations. In response to the randomised, controlled trials guidelines have been established to help guide physicians in choosing appropriate patients who may benefit from primary prevention ICDs. Unfortunately, many patients who currently fall within the guidelines are either not represented in the clinical trials or disregarded. The morbidity associated with ICD implant is also overlooked and the cost-benefit analyses are exaggerated in favour of ICD implant. This review article summarises major clinical trials addressing primary prevention ICDs, and also highlights the evidence supporting the use and abuse of ICDs.</abstract><cop>England</cop><pub>Radcliffe Medical Education Ltd</pub><pmid>26835029</pmid><doi>10.15420/aer.2012.1.46</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2050-3369
ispartof Arrhythmia & electrophysiology review, 2012-09, Vol.1 (1), p.46-50
issn 2050-3369
2050-3377
2050-3377
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4711493
source Publicly Available Content Database; PubMed Central
subjects Asymptomatic
Beta blockers
Cardiac arrhythmia
Cardiomyopathy
Cardiovascular disease
Coronary vessels
Defibrillators
Device Therapy
Heart attacks
Heart failure
Ischemia
Mortality
Prevention
Transplants & implants
title Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T19%3A16%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20and%20Abuse%20of%20Internal%20Cardioverter%20Defibrillators%20for%20Primary%20Prevention&rft.jtitle=Arrhythmia%20&%20electrophysiology%20review&rft.au=Silverstein,%20Joshua%20R&rft.aucorp=Beth%20Israel%20Deaconess%20Medical%20Center,%20Harvard%20Medical%20School,%20Boston,%20MA,%20US&rft.date=2012-09-01&rft.volume=1&rft.issue=1&rft.spage=46&rft.epage=50&rft.pages=46-50&rft.issn=2050-3369&rft.eissn=2050-3377&rft_id=info:doi/10.15420/aer.2012.1.46&rft_dat=%3Cproquest_pubme%3E1762345229%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c348t-d8b013a9b14511864b5dacae1de28242a4ec59696bad60059351bc58ca966d833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2688225372&rft_id=info:pmid/26835029&rfr_iscdi=true